Gunther A. Gastl

Innsbruck, 6020, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 66 publications

Peptide receptor radionuclide therapy alone or in combination with temozolomide plus/minus capecitabine in [18F]FDG-positive metastatic neuroendocrine tumors.

Peptide receptor radionuclide therapy alone or in combination with temozolomide plus/minus capecitabine in [18F]FDG-positive metastatic neuroendocrine tumors.

Journal: European journal of nuclear medicine and molecular imaging

Published: August 11, 2025

The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event.

The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event.

Journal: American journal of hematology

Published: August 09, 2020

Treatment According to a Comprehensive Molecular Profiling Can Lead to a Better Outcome in Heavily Pretreated Patients With Metastatic Cancer: Data of a Pooled Analysis.

Treatment According to a Comprehensive Molecular Profiling Can Lead to a Better Outcome in Heavily Pretreated Patients With Metastatic Cancer: Data of a Pooled Analysis.

Journal: Cancer journal (Sudbury, Mass.)

Published: March 22, 2019

Correction to: Ruxolitinib therapy formyelofibrosis in Austria : Consensus on therapy management.

Correction to: Ruxolitinib therapy formyelofibrosis in Austria : Consensus on therapy management.

Journal: Wiener klinische Wochenschrift

Published: December 14, 2018

Treatment According to Molecular Profiling in Relapsed/Refractory Cancer Patients: A Review Focusing on Latest Profiling Studies.

Treatment According to Molecular Profiling in Relapsed/Refractory Cancer Patients: A Review Focusing on Latest Profiling Studies.

Journal: Computational and structural biotechnology journal

Published: November 27, 2018

Cost-comparison analysis of a multiplatform tumour profiling service to guide advanced cancer treatment.

Cost-comparison analysis of a multiplatform tumour profiling service to guide advanced cancer treatment.

Journal: Cost effectiveness and resource allocation : C/E

Published: October 29, 2018

Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management.

Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management.

Journal: Wiener klinische Wochenschrift

Published: May 17, 2018

Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours.

Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours.

Journal: ESMO open

Published: April 19, 2018

Austrian recommendations for the management of polycythemia vera.

Austrian recommendations for the management of polycythemia vera.

Journal: Wiener klinische Wochenschrift

Published: March 31, 2018

Impact of white blood cells on thrombotic risk in patients with optimized platelet count in essential thrombocythemia.

Impact of white blood cells on thrombotic risk in patients with optimized platelet count in essential thrombocythemia.

Journal: European journal of haematology

Published: March 20, 2018

High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma.

High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma.

Journal: Cancer science

Published: January 23, 2018

Anti-Angiogenics: Their Value in Colorectal Cancer Therapy.

Anti-Angiogenics: Their Value in Colorectal Cancer Therapy.

Journal: Oncology research and treatment

Published: January 03, 2018

Showing 1-12 of 66

Last Updated: 09/26/2026